PH12017500239A1 - Abiraterone acetate formulation and methods of use - Google Patents

Abiraterone acetate formulation and methods of use

Info

Publication number
PH12017500239A1
PH12017500239A1 PH12017500239A PH12017500239A PH12017500239A1 PH 12017500239 A1 PH12017500239 A1 PH 12017500239A1 PH 12017500239 A PH12017500239 A PH 12017500239A PH 12017500239 A PH12017500239 A PH 12017500239A PH 12017500239 A1 PH12017500239 A1 PH 12017500239A1
Authority
PH
Philippines
Prior art keywords
methods
abiraterone acetate
acetate formulation
formulation
compositions
Prior art date
Application number
PH12017500239A
Inventor
Maura Murphy
Paul Nemeth
H William Bosch
Matthew Callahan
Satya Bhamidipati
Jason Coleman
Christopher Hill
Marck Norret
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017500239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of PH12017500239A1 publication Critical patent/PH12017500239A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
PH12017500239A 2014-09-18 2017-02-09 Abiraterone acetate formulation and methods of use PH12017500239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
PH12017500239A1 true PH12017500239A1 (en) 2017-07-03

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500239A PH12017500239A1 (en) 2014-09-18 2017-02-09 Abiraterone acetate formulation and methods of use

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102491439B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2017000098A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863500T3 (en) 2015-04-10 2021-10-11 Capsugel Belgium Nv Abiraterone Acetate Lipid Formulations
US11311493B2 (en) 2017-04-07 2022-04-26 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
CN113473974A (en) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 Pharmaceutical composition
JP2022523819A (en) 2019-03-06 2022-04-26 プロペラ セラピューティクス インコーポレイテッド Avila Teron Prodrug
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
CR20220588A (en) * 2020-05-08 2023-01-17 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
WO2022174134A1 (en) 2021-02-15 2022-08-18 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105919939A (en) * 2009-04-24 2016-09-07 伊休蒂卡有限公司 Production of encapsulated nanoparticles at commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (en) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
MX2015013247A (en) * 2013-03-15 2016-11-25 Iceutica Inc Abiraterone acetate formulation.

Also Published As

Publication number Publication date
KR102491439B1 (en) 2023-01-25
CO2017002472A2 (en) 2017-07-11
AU2015317466A1 (en) 2017-02-23
CA2958316A1 (en) 2016-03-24
BR112017003219A2 (en) 2017-11-28
TN2017000098A1 (en) 2018-10-19
KR102617537B1 (en) 2023-12-22
MX2017003525A (en) 2017-06-21
IL250270A0 (en) 2017-03-30
EP3193857A1 (en) 2017-07-26
KR20230014878A (en) 2023-01-30
TN2018000318A1 (en) 2020-01-16
WO2016044701A1 (en) 2016-03-24
EA201790650A1 (en) 2017-07-31
JP2017528457A (en) 2017-09-28
CN106687112A (en) 2017-05-17
EP3193857A4 (en) 2018-04-11
SG11201701139YA (en) 2017-03-30
MD20170048A2 (en) 2017-08-31
AP2017009804A0 (en) 2017-03-31
IL250270B (en) 2021-02-28
KR20170070025A (en) 2017-06-21

Similar Documents

Publication Publication Date Title
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
FI3674298T3 (en) Substituted indazoles, process for their preparation, pharmaceutical formulations containing them, and their use for the preparation of medicaments
MX2017006217A (en) Modulatory polynucleotides.
EP3386484A4 (en) Compositions and methods for delivery of therapeutic agents
NZ712350A (en) Abiraterone acetate formulation
CA2956871C (en) Compounds active towards bromodomains
IL273300A (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
HK1246189B (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
TN2015000411A1 (en) Ceftolozane antibiotic compositions
IN2014MU00303A (en)
EP3177286A4 (en) Compositions and methods for physiological delivery using cannabidiol
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
EP3177271A4 (en) Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
IL250306B (en) Heterocyclyl-carbonyl derivatives of indazole and pyrazolopyridine and pharmaceutical compositions comprising them
IN2014CH00840A (en)
MX2015016603A (en) Corticosteroid compositions.
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
EP3139908A4 (en) Formulations and methods for vaginal delivery of antiprogestins
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
MX2017001512A (en) Compounds active towards bromodomains.
GB201414271D0 (en) Composition for delivery of an active pharmaceutical substance and method of preparing same
MY180947A (en) Ceftolozane antibiotic compositions
IN2014CH01890A (en)
GB201415969D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof